MolecuLight^® improves success with

Looking for practical guidance on when to use MolecuLight®?

32 wound care experts joined forces to establish best practices on bacterial fluorescence imaging. Recommendations cover imaging workflow, patient selection criteria, and when and how often to use this technology.

MolecuLight® profoundly impacts the way clinicians approach wound treatment, revealing harmful bacteria and biofilm missed during routine inspection.

Providers changed their course of clinical action over half the time, most commonly extending hygiene/debridement or targeting debridement and sampling to MolecuLight® positive areas.

MolecuLight^® supports wound care equity by improving bacterial detection for all patients with any skin color.

This 350-patient clinical study validates the diagnostic accuracy of MolecuLight^® on all skin tones and reveals the inherent bias of standard assessment that underserves patients of color.

Fluorescence imaging enabled real-time monitoring of bacterial burden, guiding adjustments to NPWT and biofilm-disrupting agent treatments in recalcitrant pressure ulcer care.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

32 wound care experts collaborated in a Delphi consensus to develop guidance for bacterial fluorescence imaging. Recommendations cover imaging workflow, patient selection criteria, and when and how often to use this technology.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

MolecuLight precisely identified bacteria in pelvic pressure injuries (PIs), enhancing the understanding of PI infections, guiding treatment strategies like debridement and dressing adjustments, and enabling real-time monitoring of treatment efficacy.

The presence or absence of red or cyan on bacterial fluorescence images accurately predicted the success or failure of DFU healing after acellular matrix product placement.

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device, and fluorescence imaging before and after standard debridement revealed persistence of bacterial fluorescence in 100% of DFUs.

Fluorescence imaging demonstrated superior sensitivity (84%) and accuracy (63%) compared to clinical signs of biofilm (sensitivity 44% and accuracy 43%) and biofilm blotting (sensitivity 24% and accuracy 40%).

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

MolecuLight-guided curettage or biopsy sampling positively predicted bacterial presence in wounds at potentially harmful levels, entirely eliminating the risk of false negative sampling.

MolecuLight® shows remarkable accuracy in assessing recipient sites and predicting skin graft take/loss outcomes among burn patients.

CMS requires documentation that wounds are free of infection before skin substitute/graft application. MolecuLight® is the only tool that provides graphical evidence of adequate wound bed preparation.

MolecuLight® shows remarkable accuracy in assessing recipient sites and predicting skin graft take/loss outcomes among burn patients.

CMS requires documentation that wounds are free of infection before skin substitute/graft application. MolecuLight® is the only tool that provides graphical evidence of adequate wound bed preparation.

Twice as many diabetic foot ulcers healed after 12-weeks when MolecuLight® was used to help guide their treatment.

MolecuLight® fluorescence signals were predictive of wound outcomes, where wounds free of bacterial fluorescence achieved greater wound area reduction.